Clinical Trials Logo

Resistance, Disease clinical trials

View clinical trials related to Resistance, Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT04817280 Completed - Covid19 Clinical Trials

COVID-19 in Polish Ice Swimmers.

ICE
Start date: December 1, 2020
Phase:
Study type: Observational

Ice swimming is an increasingly common phenomenon in Poland. It has been confirmed that it has a beneficial effect on health by increasing the natural non-specific immunity to infections. In the face of the current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic causing Coronavirus Disease 2019 (COVID-19), researchers decided to use a survey to check the incidence of COVID-19 among Polish ice swimmers, as well as recent ailments. Then, the researchers will compare the obtained results with epidemiological data for Poland.Researchers will also investigate the relationship between susceptibility to SARS-CoV-2 infection and the blood group and Rh factor among ice swimmers.

NCT ID: NCT04708639 Enrolling by invitation - Lung Cancer Clinical Trials

Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients

MonAlec
Start date: June 19, 2019
Phase:
Study type: Observational

Circulating tumor DNA can be used to monitor the treatment effect and identify developing resistance mutations during ALK directed TKI treatment.

NCT ID: NCT04662996 Active, not recruiting - Prostate Cancer Clinical Trials

Search for Predictive Factors of Resistance to Treatment for Metastatic Castration-resistant Prostate Cancer by Studying the Expression of microRNAs

MiR_CPMRC
Start date: June 23, 2021
Phase: N/A
Study type: Interventional

Several drugs are available for metastatic castration resistant prostate cancer such as chemotherapy (docetaxel, cabazitaxel) and novel hormonal agents (abiraterone, enzalutamide), in France. The oncologist has to choose between those two type of treatment, without any biological predictor of efficacy for his patient. It is always difficult to choose knowing that 30 to 50% of patients won't benefit from the treatment chosen. It shows why resistant mechanisms to treatment need to be elucidated. MicroRNA (miR) are short RNA, implicated in messenger ribonucleic acid (mRNA) regulation. Evidence is emerging that miR is implicated in prostate cancer response to treatment. It would be interesting to determine if a miR profile can predict treatment response to chemotherapy and/or to novel hormonal agents.

NCT ID: NCT03400865 Not yet recruiting - Prolactinoma Clinical Trials

Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas

Start date: October 25, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to preliminarily evaluate the safety and efficacy of cabergoline combined hydroxychloroquine/chloroquine(HCQ/CQ) therapy for cabergoline-Resistant Prolactinomas